Hence, whether suppressing the constitutive expression of SELENOW, an osteoclastogenic stimulator, is effective for multiple myeloma treatments will need further pre-clinical and clinical evaluation of specific ERK mitogen-activated protein kinase inhibitors. Here, WNK2 is linked to plasma cell myeloma.